Federal contract receipt
$32,121,523 from Department of Health and Human Services to CERUS CORPORATION
LICENSE PATHOGEN REDUCTION TECHNOLOGY (PRT) FOR RED BLOOD CELL (RBC) COMPONENTS TO REDUCE THE RISK OF TRANSFUSION-TRANSMITTED INFECTION (TTI) BY RECOGNIZED, EMERGING, EPIDEMIC, AND ENDEMIC PATHOGENS THAT IS CAPABLE OF TREATING OVER 10 MILLION RBC COM
Signals
Full and openLarge awardMulti-year performance
Office of Federal Procurement Policy
Public Spend Intelligence - sledai.com
Award #CONT_AWD_75A50124C00046_7505_-NONE-_-NONE-
Signed2024-09-20
VendorCERUS CORPORATION
PlaceCA
LICENSE PATHOGEN REDUCTION TECHNOLOGY (PRT) FOR RED BLOOD CELL (RBC) COMPONENTS TO REDUCE THE RISK OF TRANSFUSION-TRANSMITTED INFECTION (TTI) BY RECOGNIZED, EMERGING, EPIDEMIC, AND ENDEMIC PATHOGENS THAT IS CAPABLE OF TREATING OVER 10 MILLION RBC COM
Total obligated$32,121,522.95
PoP Start
2024-09-30
PoP End
2029-09-30
COMPETED
Awarded on 2024-09-20
Vendor
CERUS CORPORATION
Agency
Department of Health and Human Services
Category
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Place
CA
© 2025 Sled AI Inc. All rights reserved.